Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
35 hedge funds and large institutions have $23M invested in Lumos Pharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 2 closing their positions.
22% more capital invested
Capital invested by funds: $18.8M → $23M (+$4.13M)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
3% less funds holding
Funds holding: 36 → 35 (-1)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.89M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$360K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$208K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$64.3K |
| 5 |
WFA
Wipfli Financial Advisors
Milwaukee,
Wisconsin
|
+$8.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$503K |
| 2 |
WAOI
Wealth Advisors of Iowa
West Des Moines,
Iowa
|
-$194K |
| 3 |
Renaissance Technologies
New York
|
-$163K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$128K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$83.1K |
LUMO Hedge Fund Activity: Q3 2022 in Review
35 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2022, worth a combined $23M — up 22% from $18.8M a quarter earlier.
Fund positioning in LUMO was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.89M. The largest seller was NEA Management Company, exiting entirely with an estimated $503K sold.
- 35 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2022, down from 36 in Q2 2022.
- Funds reported $23M of Lumos Pharma, Inc. Common Stock stock for Q3 2022, up 22% quarter-over-quarter.
- 2 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2022 was Goldman Sachs, an estimated $1.89M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2022 was NEA Management Company, an estimated $503K sold.
Based on aggregated 13F filings for Q3 2022.